#HCG 🧵to provide key technical analysis insight & learning through one of popular stock HCG (valid for long term investors & traders)
Please note there are no GOD rules in technical analysis, but discipline makes a rule GOD for us when transactions go for a toss
Keep reading..
Let us focus on 2 things: 1. Why as an investor I start any chart reading with monthly chart for longer term direction
2. Why relative performance matters
1. Importance of monthly charts: peaceful investing without much churn in portfolio and daily tracking (this is one of the ways, not the only way or best way to take decisions).
a. Exit: If one would have simply plotted relative performance with respect to NIFTY, he would
have got out in early 2018 and avoided whole decline and underperformance for next 2 years
b. Entry: Further, in June 2020, would have taken entry based on outperformance to NIFTY and would have continued to outperform NIFTY
c. Average up: Whenever stocks relative performance came at par with NIFTY, it created a temporary bottom and next leg of run from there
2. Why relative performance matters:
NIFTY return itself has been respectable 12-14% over long term and if one can outperform this without much fuss and peace of mind with lesser churn, not a bad idea. Relative strength performance analysis helps to ideate the same
Currently, HCG has started underperforming NIFTY though not by a heavy margin but for last few months unless last few times when it rebounded quickly. No one will know the future but it is all about discipline of well tested rules which a protection cover to save from big falls
and ride big gains.
So, this was all about blending 2 concepts - relative strength and longer timeframes to simplify some of the concepts.
At Scientific Investing, we love to teach many such concepts and will be teaching in detail through our CMT level study sessions and much more in our practitioner membership. You can explore the same here. learn.scientificinvesting.in/learn/SI-PRACT…
Also, we love to teach about rule building, quantification, back testing, building systems and algorithms picking such ideas in our QUANTS learning track. You can explore it here. learn.scientificinvesting.in/learn/QUANTECH
Like and share if this was useful for wider reach🙏
Remember the key message - Its not about predicting a perfect buy or sell call or trying to predict HCG ka kya hoga. The key message is bigger and about patterns/rules/discipline and systems - focus there
Also, think more, conclude less - Killing all this analysis above - Why it looked so beautiful - because either the stock was in continuous uptrend or downtrend. The moment it goes no where for month doing criss cross, the rule may become pain in the ass which means it needs
more thoughts. Think about it. My goal is only to make you think and not talk about what will happen to HCG or what a great or crappy rule is this. There is nothing perfect but there are always better solutions n possibility for improvement
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#Ultramarine Annual Report 2025 #AR2025 and some fun facts and why we should look beyond numbers visible to all:
Screener PE: 19.7
PE is based on EPS growth derived from P&L. However, if a business has: 1. High accounting depreciation but low actual maintenance 2. Lot of capex done recently resulting in high depreciation with scope of better asset utilization in times to come
PCE (Price to Cash EPS, a term purely coined on own and not in valuation books) could be a better reference point. There are many situations where PCE either based on cash EPS of OCF based is a better representation of valuation.
When we look Ultramarine from OCF perspective, Ultramarine did Rs 90 Cr of OCF,
Earlier PE: 19.7
OCF based PE/PCE: 15.5-16.5
Below is cashflow statement from AR 2025
It does not stop here. When one looks at the balance sheet of the company, there is something interesting. It has a non-current investment of Rs 498 Cr
This investment is for the value of 20% stake they hold in sister company Thirumalai chemicals.
This is also evident when you look at Thirumalai shareholding. Thirumalai current market cap is Rs ~Rs 2900 Cr. So, this shareholding value comes to Rs 580 Cr as on today. Give 50% holdo discount and this value for Ultramarine comes to Rs 290 Cr
Yesterday, I shared this data point of % of companies hitting 52 week low close to ILFS Oct 2018 number.
Question is what is the significance of this data?
Let us explore
The reason to share this data is much more interesting. In current market, people would say - do not catch falling knife, let it bottom etc.
What if you invested in all those days when more than 20% companies were making 52 week low?
Can you backtest return of all such scenarios since last 10-20 years?
Got reminded of my Face2Face video done 4 years back where I presented lot of backtested outputs including how your returns would pan out
Here is this data right from 2006. The red bars are % of companies making 52W low
Though some of these metric are gaining popularity now, we had done lot of exploratory analysis and backtesting around these metric 4-5 years back when I was conceptualizing Scientific Investing . You can watch the full video here:
For SMALLCAP 250, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY NEXT 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
1/15 🚀 Introducing Aarti Pharmalabs Ltd!
They make APIs, Xanthine Derivatives, and offer CDMO/CMO services for drug development and manufacturing.
Let’s break it down step by step! 🧵👇
2/15 🏢 Company Background:
● Originally part of Aarti Industries, Aarti Pharmalabs became a separate entity in 2022.
● Focus: Manufacturing key pharmaceutical ingredients, intermediates, and offering contract manufacturing for drug development.
● Their goal? To supply high-quality ingredients for medicines, energy drinks, and supplements globally.
3/15 🌿 What are APIs (Active Pharmaceutical Ingredients)?
● APIs are the active components in medicines that provide therapeutic effects.
○ Example: The ingredient in cancer, pain relief, and respiratory drugs.
● Intermediates are chemical compounds used to create APIs.
○ Think of intermediates as the building blocks of medicines
➡️ Aarti manufactures both!